Selinexor

BrightSpring Health Services’ Specialty Pharmacy Onco360® Celebrates Excellent Patient Care and Preferred Pharmacy Status

Retrieved on: 
Thursday, March 14, 2024
Diagnosis, Health care, Disease, Selinexor, Partnership, Patient, Pharmacy, Multiple myeloma, Pharmacist, Cancer, B cell, NPS, Insurance, Patient satisfaction, DLBCL, Health, Hospital

“At BrightSpring Health Services, we are proud of our leading service lines like Onco360® as we continue to innovate in the health care industry and provide patients with life-improving and life-sustaining treatments,” said BrightSpring President and CEO Jon Rousseau.

Key Points: 
  • “At BrightSpring Health Services, we are proud of our leading service lines like Onco360® as we continue to innovate in the health care industry and provide patients with life-improving and life-sustaining treatments,” said BrightSpring President and CEO Jon Rousseau.
  • “It is an honor for Onco360® to be selected as the preferred pharmacy for XPOVIO® (selinexor) and shows the Company’s dedication to innovation, quality patient care and improving health outcomes.
  • Onco360® and its dedicated employees do a fantastic job of keeping BrightSpring’s important mission at the core of everything they do.”
    As another demonstration of BrightSpring and Onco360®’s commitment to patient care, this year, Onco360® celebrates excellent service and care that resulted in unmatched patient satisfaction scores.
  • “It’s incredibly important to us to provide patient care that prioritizes expertise, reliability, consistency, and overall satisfaction,” said Benito Fernandez, Chief Commercial Officer at Onco360®.

Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO® (selinexor)

Retrieved on: 
Wednesday, March 13, 2024
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Diagnosis, B-cell lymphoma, Dexamethasone, Selinexor, Partnership, Bortezomib, Patient, Carfilzomib, National Cancer Institute, Multiple myeloma, B cell, Lenalidomide, Daratumumab, Therapy, Bone marrow, Food, FDA, DLBCL, Follicular lymphoma, Pharmaceutical industry

Onco360®, the nation’s largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Karyopharm’s product XPOVIO® (selinexor), a first-in-class, XPO-1 inhibitor.

Key Points: 
  • Onco360®, the nation’s largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Karyopharm’s product XPOVIO® (selinexor), a first-in-class, XPO-1 inhibitor.
  • “Onco360 is excited to expand our partnership with the team at Karyopharm and become the preferred national specialty pharmacy partner for XPOVIO,” said Benito Fernandez, Chief Commercial Officer.
  • Multiple myeloma is an incurable hematological malignancy involving plasma cells.
  • Only 50 percent of patients diagnosed with multiple myeloma survive past five years following initial diagnosis.

Florida Cancer Specialists & Research Institute Shares Pharmacy Expertise To Advance Medically Integrated Oncology Care

Retrieved on: 
Wednesday, April 3, 2024
Real-World Evidence, RN, Success, BP, RRMM, Doctor of Pharmacy, BCPS, Selinexor, Incidence, Partnership, Physician, Manufacturing, Bachelor of Pharmacy, DNP, Nursing, Prior authorization, Pharmacist, Roger Hawkins (drummer), CAPM, MPA, BSN, Therapy, RPH, Pharmacy, Outcome, Safety, Infrared spectroscopy correlation table, Best practice, FCS, PACS, OCN, Data, Metric, Health care

FORT MYERS, Fla., April 3, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) leaders and pharmacy experts will share insights and best practices in specialty pharmacy operations and dispensing that are contributing to positive patient outcomes at the NCODA 2024 Spring Forum in Dallas. The focus of the multi-day gathering, "Driving Optimal Strategies for Patient Care in Medically Integrated Oncology," is on the vital role of pharmacy involvement throughout the entire cancer care continuum.

Key Points: 
  • The focus of the multi-day gathering, "Driving Optimal Strategies for Patient Care in Medically Integrated Oncology," is on the vital role of pharmacy involvement throughout the entire cancer care continuum.
  • "Our Rx To Go team members continue to set the standard of excellence for medically-integrated oncology pharmacy and support services," said FCS President & Managing Physician Lucio Gordan, MD .
  • "They are well-equipped to contribute top-tier knowledge to help steer the future of oncology care."
  • NCODA is a globally recognized not-for-profit organization dedicated to building a patient-centered, medically integrated community of health care providers whose focus is to innovate the continuity of cancer care so that every patient receives the maximum benefit from their cancer treatment.

Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Retrieved on: 
Wednesday, December 6, 2023
NDA, Dexamethasone, Immunotherapy, NCCN, Disease, Hematology, Proteasome inhibitor, ESMO, Diagnosis, Multiple myeloma, International Myeloma Foundation, Patient, Guideline, Chinese, XPO1, Therapy, Selinexor, Oncology, Growth, CSCO, Pi, HIV disease progression rates, Pharmaceutical industry, Medical device

XPOVIO® has received regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.

Key Points: 
  • XPOVIO® has received regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.
  • XPOVIO® is the world's first oral selective inhibitor of the nuclear export protein XPO1, with regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.
  • "Antengene is excited to receive approval of XPOVIO® in Macau, first in the next wave of expected approvals in the APAC."
  • I am glad that XPOVIO® has become the first and only XPO1 inhibitor approved for the treatment of patients with R/R MM in Macau China.

Mestag Therapeutics announces the appointment of expert advisors Dr. Cassandra Choe-Juliak, Dr. Greg Elson and Samantha Vieira MBA

Retrieved on: 
Thursday, October 12, 2023
Bachelor of Science, Ipsen, Bispecific monoclonal antibody, Affimer, MBA, Receptor (biochemistry), Acquisition, Doctor of Philosophy, MS, Development, Henley Business School, Breast, PMP, Multiple myeloma, University, AMAL, VCU Medical Center, Boehringer, Glenmark Pharmaceuticals, Biosimilar, Therapy, Georgetown University, Medical college, Merck, University of the Witwatersrand, Nightstar, Publication, Biogen, Lung, Selinexor, EMBA, Boehringer Ingelheim, XPO, Patient, Pharmaceutical industry, Molecular Immunology, Physiology, MD

"Mestag is honored to appoint Dr. Choe-Juliak, Dr. Elson and Ms Vieira to our advisory team.

Key Points: 
  • "Mestag is honored to appoint Dr. Choe-Juliak, Dr. Elson and Ms Vieira to our advisory team.
  • Cassandra Choe-Juliak, MD, MS, has spent more than 17 years in oncology medical affairs and clinical drug development.
  • Greg Elson, PhD, is co-founder and managing partner at Prevail Biopharma Solutions, and Chief Technology Officer at Alentis Therapeutics.
  • Samantha holds an EMBA from Henley Business School and BSc (Honours) in Physiology from University of the Witwatersrand, South Africa.

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

Retrieved on: 
Friday, June 9, 2023
Safety, Rash, Selinexor, Dor, Lipase, Patient, Risk, Pneumonia, EZH2, PFS, Pharmaceutical industry

Because of its high target selectivity and optimal PK profile, amdizalisib has the potential to demonstrate an optimal benefit-risk profile in this class.

Key Points: 
  • Because of its high target selectivity and optimal PK profile, amdizalisib has the potential to demonstrate an optimal benefit-risk profile in this class.
  • Here we report updated results from a Phase Ib study of amdizalisib in patients with various subtypes of non-Hodgkin’s lymphoma (“NHL”).
  • PFS and DoR from the MZL cohort were presented for the first time, at median follow-up duration of 20.3 months.
  • Median DoR was not reached and median PFS was 26.8 months for the 16 efficacy evaluable patients in the MZL cohort.

Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at AACR 2023

Retrieved on: 
Tuesday, April 18, 2023
Neutropenia, Ruxolitinib, AACR, Primary myelofibrosis, Icahn School of Medicine at Mount Sinai, Week, JAK, XPO1, American Association for Cancer Research, Mount Sinai, February 24, Doctor of Philosophy, Bone marrow, Selinexor, KPTI, Incidence, City, Jaki, Spleen, MD, Patient, Anemia, Host, Peripheral neuropathy, Nausea, Therapy, Safety, Thrombocytopenia, Fatigue, Dietary supplement, Pharmaceutical industry, Medicine

NEWTON, Mass., April 18, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced updated results from the Phase 1 study evaluating the safety and efficacy of once-weekly selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis (NCT04562389). The data, featured in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, show that rapid, deep and sustained spleen responses and robust symptom improvement were achieved at both weeks 12 and 24, in patients treated with  selinexor 60mg in combination with ruxolitinib.

Key Points: 
  • As of the February 24, 2023 data cut-off date, 24 patients had been assigned to either a 40mg or 60mg once weekly dose of selinexor, combined with ruxolitinib.
  • SVR35 responses were observed in 100% of evaluable patients at any time and rates were consistent regardless of subgroups, including males and patients treated with low dose ruxolitinib.
  • Dr. Mascarenhas will discuss the relevance of the updated data with selinexor in combination with ruxolitinib to the current treatment landscape and unmet medical need in treating patients with myelofibrosis.
  • He will also describe the design of the Company's selinexor and ruxolitinib Phase 3 study as the study's primary investigator.

Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 3, 2023
Annual report, Compugen (Israeli company), Patient, NDAS, Hematology, Greater, Selinexor, Conference, SEHK, Hong Kong Stock Exchange, PST, IND, Therapy, NDA, Risk, Pharmaceutical industry

SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that Antengene will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th, 2023 at 9:30 a.m. PST in San Francisco, California.

Key Points: 
  • SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that Antengene will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th, 2023 at 9:30 a.m. PST in San Francisco, California.
  • The presentation will be made by Dr. Jay Mei, Antengene's Founder, Chairman and CEO.
  • Details of the event are as follow:
    An archived version of the presentation also will be available on the Company website following the live presentation.
  • You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect.

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Tuesday, December 27, 2022
MSD, ICIS, Merck Sharp & Dohme Federal Credit Union, Annual report, Compugen (Israeli company), Patient, Tumor microenvironment, Toxicology, Merck, NDAS, Hematology, Greater, Selinexor, Adenosine, Safety, SEHK, Hong Kong Stock Exchange, GLP, Pembrolizumab, Pharmacology, IND, Therapy, NDA, Cancer, Agreement, Risk, Merck & Co., Immunosuppression, CD73, Pharmaceutical industry

SHANGHAI and HONG KONG, Dec. 26, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, today announced it has entered into a global clinical collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) on a multicenter, open-label, Phase I dose-finding study of ATG-037 as a monotherapy and in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with locally advanced or metastatic solid tumors (the STAMINA-001 study).

Key Points: 
  • Secondary objectives of the study include the characterization of the pharmacology and evaluation of preliminary efficacy of ATG-037.
  • Under the terms of the Agreement, the study will be conducted by Antengene, and MSD will provide KEYTRUDA® for the combination portions of the trial.
  • The patient enrollment for the Phase I study of ATG-037 is currently underway in Australia.
  • ATG-037 has demonstrated promising preclinical efficacy as a monotherapy and in combination with immune checkpoint inhibitors (ICIs) and chemotherapy agents.

Myelofibrosis Market is Expected to Grow at a CAGR of 7.3% by 2032 | DelveInsight

Retrieved on: 
Monday, December 19, 2022
Thrombocythemia, Chronic leukemia, Physical examination, Bristol Myers Squibb, Fibroblast, Patient, GIST, Vomiting, Multiple myeloma, Bruise, B cell, Bone marrow, Lymphoma, LAS, Abdomen, Roche, Weight loss, Swelling, Bleeding, Anemia, Diagnosis, Transient myeloproliferative disease, XPO1, Abbreviated New Drug Application, Primary myelofibrosis, Novartis, FDA, Degenerative disease, Polycythemia, Geron Corporation, United Kingdom, Fatigue, Ruxolitinib, NDA, Selinexor, GSK, Infection, Nausea, AbbVie, Acute leukemia, MorphoSys, New Drug Application, Bone marrow failure, Symptoms of COVID-19, Abdominal pain, Pharmaceutical industry, Lithium

LAS VEGAS, Dec. 19, 2022 /PRNewswire/ -- DelveInsight's Myelofibrosis Market Insights report includes a comprehensive understanding of current treatment practices, myelofibrosis emerging drugs, market share of individual therapies, and historical, current as well as forecasted myelofibrosis market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan].

Key Points: 
  • The myelofibrosis market is expected to grow at a faster rate due to increased awareness and increase in novel discoveries.
  • The expected launch of potential emerging therapies will boost the myelofibrosis market during the forecast period (2022–2032) in the 7MM.
  • According to the assessment done by DelveInsight, the estimated total myelofibrosis prevalent population in the 7MM was approximately 39.7K in 2021.
  • The myelofibrosis market size is expected to increase owing to the increase in the prevalent population of myelofibrosis patients in the 7MM.